Ticker Details
Coherus BioSciences, Inc. Coherus BioSciences Inc is a biotechnology company that develops biosimilar therapeutics. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines.
IPO Date:	November 6, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$272.8M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.37 | 3.12%
Avg Daily Range (30 D):	$0.05 | 3.13%
Avg Daily Range (90 D):	$0.06 | 3.51%

Institutional Daily Volume
Avg Daily Volume:	1.15M
Avg Daily Volume (30 D):	1.06M
Avg Daily Volume (90 D):	1.65M

Trade Size
Avg Trade Size (Sh.):	161
Avg Trade Size (Sh.) (30 D):	221
Avg Trade Size (Sh.) (90 D):	262

Institutional Trades
Total Institutional Trades:	3,199
Avg Institutional Trade:	$1.5M
Avg Institutional Trade (30 D):	$1.07M
Avg Institutional Trade (90 D):	$1.04M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.76M
Avg Closing Trade (30 D):	$1.57M
Avg Closing Trade (90 D):	$.88M
Avg Closing Volume:	159.49K

News

Feb 17, 2026 @ 9:11 PM Coherus Oncology, Inc. Announces Closing of Public... Source: Globe Newswire

Feb 13, 2026 @ 2:18 AM Coherus Oncology, Inc. Announces Pricing of Public... Source: Na

Nov 6, 2025 @ 6:54 PM Arvind Sood joins Coherus Oncology as Chief Strate... Source: Denny Lanfear

Apr 1, 2025 @ 12:00 PM Coherus Announces Repurchase of Approximately $170... Source: Coherus Biosciences, Inc.

Jul 30, 2024 @ 5:00 PM Hepatic Tumor Clinical Trial Pipeline Experiences ... Source: Delveinsight

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$1.43	$-.34	$1.43
Diluted EPS	$1.43	$-.34	$1.43
Revenue	$42.17M	$12.75M	$42.17M
Gross Profit	$28.36M	$8.7M	$28.36M
Net Income / Loss	$168.02M	$-37.64M	$168.02M
Operating Income / Loss	$-181.13M	$-45.88M	$-181.13M
Cost of Revenue	$13.81M	$4.05M	$13.81M
Net Cash Flow	$-37.13M	$-14.47M	$-37.13M
PE Ratio